MRVI:NASDAQMaravai LifeSciences Holdings, Inc. Analysis
Data as of 2026-08-14 - not real-time
$5.70
Latest Price
8/10Risk
Risk Level: High
Executive Summary
Maravai LifeSciences Holdings, Inc. is priced at $5.70 and its moving averages line up in bullish order, the shorter sitting above the longer. Across the trailing 30 sessions it lost 7.3%. With RSI at 34.2 the momentum picture is approaching oversold, alongside a bearish MACD signal. Price has been bracketed by support at $5.41 and resistance at $7.44.
The company is not currently profitable on a trailing basis, so earnings multiples offer no valuation support. The average analyst target implies 28.1% above today's level. Revenue is growing at 8.5% on a -37.1% profit margin.
On a 1-10 scale the risk profile lands at 8 — high. With 30-day volatility of 45.3%, a beta of 1.34 and a maximum drawdown of 29.6%, position sizing matters more than entry timing here. The wider market backdrop reads extreme greed at 96 on the fear-greed composite.
All three time horizons resolve to hold, carrying 2/10 conviction.
The company is not currently profitable on a trailing basis, so earnings multiples offer no valuation support. The average analyst target implies 28.1% above today's level. Revenue is growing at 8.5% on a -37.1% profit margin.
On a 1-10 scale the risk profile lands at 8 — high. With 30-day volatility of 45.3%, a beta of 1.34 and a maximum drawdown of 29.6%, position sizing matters more than entry timing here. The wider market backdrop reads extreme greed at 96 on the fear-greed composite.
All three time horizons resolve to hold, carrying 2/10 conviction.
Top Market Events
Updated Jul 22, 2026 0 SAN DIEGO-- BUSINESS WIRE --Jul 22, 2026-- Maravai LifeSciences, Inc.Updated Jun 3, 2026 0 SAN DIEGO-- BUSINESS WIRE --Jun 3, 2026-- Maravai LifeSciences Holdings, Inc.Joplin Globe23dMaravai LifeSciences To Host Earnings Conference Call on Thursday, August 6, 2026Maravai LifeSciences,...
Market Outlook
Short Term
< 1 yearNeutral
Model confidence: 2/10
Key Factors
- Short-term moving averages stacked above long-term ones
- Trading above the 200-day average of 4.15
- MACD momentum is negative
Medium Term
1–3 yearsNeutral
Model confidence: 1/10
Key Factors
- Short-term moving averages stacked above long-term ones
- Trading above the 200-day average of 4.15
- Analyst targets imply +28.1% versus the current price
Long Term
> 3 yearsNeutral
Model confidence: 2/10
Key Factors
- Negative profit margin of -37.1%
- Analyst targets imply +28.1% versus the current price
- Negative return on equity of -33.0%
Key Metrics & Analysis
Financial Health
Revenue Growth8.50%
Profit Margin-37.07%
P/E Ratio-56.8
ROE-33.05%
ROA-5.71%
Debt/Equity61.34
P/B Ratio4.0
Op. Cash Flow$-25261000
Free Cash Flow$-3623125
Industry P/E29.8
Technical Analysis
TrendBullish
RSI34.2
Support$5.41
Resistance$7.44
MA 20$6.54
MA 50$6.03
MA 200$4.15
MACDBearish
VolumeDecreasing
Fear & Greed Index95.98
Valuation
Target Price$7.30
Upside/Downside28.07%
GradeFair
TypeBlend
Risk Assessment
Beta1.34
Volatility45.26%
Sector RiskMedium
Reg. RiskHigh
Geo RiskLow
Currency RiskLow
Liquidity RiskMedium
Similar Tickers
This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.